IP Library › Granted Patent US 12,559,566
Granted Patent B2
US 12,559,566 · App. 17/938,886 · Granted Feb 24, 2026

CD37-binding molecules immunoconjugates thereof

Inventors: Jutta Deckert (Lexington, MA); Peter Park (Somerville, MA); Daniel Tavares (Natick, MA); Lingyun Rui (Weston, MA)
Assignee: DEBIOPHARM INTERNATIONAL, S.A.
C07K16/2896A61K47/60A61K47/68033A61K47/6817A61K47/6849A61K47/6867C07K16/30G01N33/566A61K2039/505C07K2317/24C07K2317/33C07K2317/56C07K2317/565C07K2317/60C07K2317/73C07K2317/732C07K2317/734C07K2317/92G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,566
App. No.
17/938,886
Granted
Feb 24, 2026
Kind
B2
Abstract

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

Claims (30)

1 . An isolated antibody or antigen binding fragment thereof that specifically binds to CD37, wherein said antibody or antigen binding fragment thereof comprises:

i) the VH polypeptide sequence of SEQ ID NO: 57; and the VL-CDR1, VL-CDR2, and VL-CDR3 polypeptide sequences of SEQ ID NOs: 28, 29, and 30 respectively; or

ii) the VH-CDR1, VH-CDR2, and VH-CDR3 polypeptide sequences of SEQ ID NOs: 4, 5, and 6 respectively; and the VL polypeptide sequence of SEQ ID NO: 74.

2 . An isolated antibody thereof that specifically binds to CD37, wherein said antibody comprises the polypeptide sequences of SEQ ID NO:57 and SEQ ID NO:74, and wherein the antibody comprises an IgG1 constant region and/or a human IgG1 constant region.

3 . An immunoconjugate having the formula (A)-(L)-(C), wherein:

(A) is the isolated antibody or antigen binding fragment thereof of claim 1 ;

(L) is a linker; and

(C) is a cytotoxic agent; and

wherein said linker (L) links (A) to (C).

4 . The immunoconjugate of claim 3 , wherein said cytotoxic agent is N(2′)-deacetyl-N(2′)-(3-mercapto-1-oxopropyl)-maytansine (DM1).

5 . An immunoconjugate having the formula (A)-(L)-(C), wherein:

(A) is the isolated antibody of claim 2 ;

(L) is a linker; and

(C) is a cytotoxic agent; and

wherein said linker (L) links (A) to (C).

6 . The immunoconjugate of claim 5 , wherein said cytotoxic agent is N(2′)-deacetyl-N(2′)-(3-mercapto-1-oxopropyl)-maytansine (DM1).

7 . A pharmaceutical composition comprising the immunoconjugate of claim 3 and a pharmaceutically acceptable carrier.

8 . The pharmaceutical composition of claim 7 , wherein the immunoconjugates have an average of about 3 to about 4 (C) per (A).

9 . A pharmaceutical composition comprising the immunoconjugate of claim 5 and a pharmaceutically acceptable carrier.

10 . The pharmaceutical composition of claim 9 , wherein the immunoconjugates have an average of about 3 to about 4 (C) per (A).

11 . An isolated cell producing the isolated antibody or antigen binding fragment thereof of claim 1 .

12 . A method of making an anti-CD37 antibody or antigen-binding fragment thereof comprising (a) culturing the cell of claim 11 ; and (b) isolating said antibody or antigen-binding fragment thereof from said cultured cell.

13 . An isolated cell producing the isolated antibody of claim 2 .

14 . A method of making an anti-CD37 antibody comprising (a) culturing the cell of claim 13 ; and (b) isolating said antibody from said cultured cell.

15 . A method for inhibiting the growth of a cell expressing CD37 comprising contacting the cell with the immunoconjugate of claim 3 .

16 . A method for treating a patient having cancer comprising administering to said patient a therapeutically effective amount of the immunoconjugate of claim 3 , wherein said cancer is characterized by CD37 expression.

17 . A method for inhibiting the growth of a cell expressing CD37 comprising contacting the cell with the immunoconjugate of claim 5 .

18 . A method for treating a patient having cancer comprising administering to said patient a therapeutically effective amount of the immunoconjugate of claim 1 , wherein said cancer is characterized by CD37 expression.

19 . An antibody or antigen-binding fragment thereof produced by the method of claim 12 .

20 . An antibody or antigen-binding fragment thereof produced by the method of claim 14 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2023
From: IMMUNOGEN, INC.
To: DEBIOPHARM INTERNATIONAL, S.A.
Reel/Frame 062263/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2023
From: DECKERT, JUTTA; PARK, PETER; TAVARES, DANIEL; RUI, LINGYUN
To: IMMUNOGEN, INC.
Reel/Frame 062266/0500 →
Continuity (8)
Continuation 16221747 · Dec 17, 2018
Division 15130667 · Apr 15, 2016
Division 13796768 · Mar 12, 2013
Division 13045693 · Mar 11, 2011
Provisional Application 61412644 · Nov 11, 2010
Provisional Application 61327314 · Apr 23, 2010
Provisional Application 61313628 · Mar 12, 2010
Related Publication 20230287137A1 · Sep 14, 2023
References Cited (273)
US 5122368A · Greenfield et al. · 1992 [cited by applicant]
US 5595756A · Bally · 1997 [cited by applicant]
US 7303749B1 · Chari · 2007 [cited by applicant]
US 7585491B2 · Govindan · 2009 [cited by applicant]
US 7601354B2 · Chari et al. · 2009 [cited by applicant]
US 7989598B2 · Steeves et al. · 2011 [cited by applicant]
US 8088387B2 · Steeves et al. · 2012 [cited by applicant]
US 8765917B2 · Deckert et al. · 2014 [cited by applicant]
US 9346887B2 · Deckert et al. · 2016 [cited by applicant]
US 9447189B2 · Deckert et al. · 2016 [cited by applicant]
US 10202460B2 · Deckert et al. · 2019 [cited by applicant]
US 10556958B2 · Deckert et al. · 2020 [cited by applicant]
US 11395796B2 · Romanelli et al. · 2022 [cited by applicant]
US 11466095B2 · Deckert · 2022 [cited by examiner]
US 20030114398A1 · Chatterjee et al. · 2003 [cited by applicant]
US 20040166115A1 · Griffiths et al. · 2004 [cited by applicant]
US 20050136049A1 · Ledbetter et al. · 2005 [cited by applicant]
US 20050287538A1 · Cheung et al. · 2005 [cited by applicant]
US 20060039913A1 · Das et al. · 2006 [cited by applicant]
US 20060233822A1 · Xia et al. · 2006 [cited by applicant]
US 20060263349A1 · Mccutcheon et al. · 2006 [cited by applicant]
US 20070009519A1 · Hariharan et al. · 2007 [cited by applicant]
US 20070059306A1 · Grosmaire et al. · 2007 [cited by applicant]
US 20070237779A1 · Ledbetter et al. · 2007 [cited by applicant]
US 20070270585A1 · Chari et al. · 2007 [cited by applicant]
US 20080075726A1 · Smith et al. · 2008 [cited by applicant]
US 20080226626A1 · Hariharan et al. · 2008 [cited by applicant]
US 20080227198A1 · Hariharan et al. · 2008 [cited by applicant]
US 20080279850A1 · Brady et al. · 2008 [cited by applicant]
US 20080311676A1 · Brate · 2008 [cited by examiner]
US 20090041783A1 · Takayama et al. · 2009 [cited by applicant]
US 20090136516A1 · Tedder et al. · 2009 [cited by applicant]
US 20090148447A1 · Ledbetter et al. · 2009 [cited by applicant]
US 20090175867A1 · Thompson et al. · 2009 [cited by applicant]
US 20090269336A1 · Hong et al. · 2009 [cited by applicant]
US 20090274692A1 · Tan et al. · 2009 [cited by applicant]
US 20090274713A1 · Chari et al. · 2009 [cited by applicant]
US 20100034820A1 · Ledbetter et al. · 2010 [cited by applicant]
US 20100135900A1 · Cerveny et al. · 2010 [cited by applicant]
US 20100189722A1 · Heider et al. · 2010 [cited by applicant]
US 20110256056A1 · Alper et al. · 2011 [cited by applicant]
US 20110256153A1 · Deckert et al. · 2011 [cited by applicant]
US 20120020963A1 · Banchereau et al. · 2012 [cited by applicant]
US 20120020983A9 · Braun et al. · 2012 [cited by applicant]
US 20120276119A1 · Deckert et al. · 2012 [cited by applicant]
US 20130058947A1 · Stull et al. · 2013 [cited by applicant]
US 20130295104A1 · Deckert et al. · 2013 [cited by applicant]
US 20140120083A1 · Stern et al. · 2014 [cited by applicant]
US 20140170063A1 · Govindan et al. · 2014 [cited by applicant]
US 20140348745A1 · Larsen et al. · 2014 [cited by applicant]
US 20150093397A1 · Carrigan · 2015 [cited by applicant]
US 20150343077A1 · Deckert et al. · 2015 [cited by applicant]
US 20160326258A1 · Deckert et al. · 2016 [cited by applicant]
US 20160340438A1 · Deckert et al. · 2016 [cited by applicant]
US 20170000900A1 · Romanelli et al. · 2017 [cited by applicant]
US 20180244795A1 · Deckert et al. · 2018 [cited by applicant]
US 20190183788A1 · Romanelli et al. · 2019 [cited by applicant]
US 20200054763A1 · Bertoni et al. · 2020 [cited by applicant]
US 20200270361A1 · Deckert et al. · 2020 [cited by applicant]
US 20200330604A1 · Li et al. · 2020 [cited by applicant]
US 20210196835A1 · Rouits et al. · 2021 [cited by applicant]
CN 1446104A · 2003 [cited by applicant]
CN 1494433A · 2004 [cited by applicant]
CN 1568198A · 2005 [cited by applicant]
EP 0328147B1 · 1994 [cited by applicant]
JP 2006513203A · 2006 [cited by applicant]
JP 2016536298A · 2016 [cited by applicant]
WO WO0124763A2 · 2001 [cited by applicant]
WO WO0204021A1 · 2002 [cited by applicant]
WO WO02060484A1 · 2002 [cited by applicant]
WO WO02060485A2 · 2002 [cited by applicant]
WO WO02102972A2 · 2002 [cited by applicant]
WO WO03048306A2 · 2003 [cited by applicant]
WO WO03083069A2 · 2003 [cited by applicant]
WO WO2004058298A1 · 2004 [cited by applicant]
WO WO2005017148A1 · 2005 [cited by applicant]
WO WO2005037989A2 · 2005 [cited by applicant]
WO WO2005037992A2 · 2005 [cited by applicant]
WO WO2006074397A2 · 2006 [cited by applicant]
WO WO2006133450A2 · 2006 [cited by applicant]
WO WO2007014278A2 · 2007 [cited by applicant]
WO WO2007077173A1 · 2007 [cited by applicant]
WO WO2007140371A2 · 2007 [cited by applicant]
WO WO2007146968A2 · 2007 [cited by applicant]
WO WO2008052030A2 · 2008 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009019312A2 · 2009 [cited by applicant]
WO WO2009065576A1 · 2009 [cited by applicant]
WO WO2009085576A2 · 2009 [cited by applicant]
WO WO2009126858A2 · 2009 [cited by applicant]
WO WO2009126944A1 · 2009 [cited by applicant]
WO WO2009134977A1 · 2009 [cited by applicant]
WO WO2010008726A1 · 2010 [cited by applicant]
WO WO2010009124A2 · 2010 [cited by applicant]
WO WO2010126551A1 · 2010 [cited by applicant]
WO WO2011090754A1 · 2011 [cited by applicant]
WO WO2011090762A1 · 2011 [cited by applicant]
WO WO2011100398A1 · 2011 [cited by applicant]
WO WO2011100403A1 · 2011 [cited by applicant]
WO WO2011112978A1 · 2011 [cited by applicant]
WO WO2012135740A2 · 2012 [cited by applicant]
WO WO2013149171A2 · 2013 [cited by applicant]
WO WO2013171289A1 · 2013 [cited by applicant]
WO WO2014143807A2 · 2014 [cited by applicant]
WO WO2014195460A1 · 2014 [cited by applicant]
WO WO2014197411A1 · 2014 [cited by applicant]
WO WO2015038777A1 · 2015 [cited by applicant]
WO WO2015067586A2 · 2015 [cited by applicant]
WO WO2015116729A2 · 2015 [cited by applicant]
WO WO2015175533A2 · 2015 [cited by applicant]
WO WO2016200676A1 · 2016 [cited by applicant]
WO WO2017040247A1 · 2017 [cited by applicant]
WO WO2018083633A1 · 2018 [cited by applicant]
WO WO2019229677A1 · 2019 [cited by applicant]
Altschuler, E.P., et al., “Method for Obtaining Recombinant Antibodies and for Improving Affinities Thereof,” Uspehi biologicheskoi himii 50: 203-258, Pleiades Publishing Ltd., Russia (Dec. 2010). [cited by applicant]
Altshuler, E.P., et al., “Generation of Recombinant Antibodies and Means for Increasing Their Affinity,” Biochemistry 75(13):1584-1605, Pleiades Publishing, Ltd., United States (Dec. 2010). [cited by applicant]
Angeletti, R.H., “Design of Useful Peptide Antigens,” Journal of Biomolecular Techniques 10(1):2-10, Association of Biomolecular Resource Facilities, United States (1999). [cited by applicant]
Angelisova, P., et al., “Association of Four Antigens of the Tetraspans Family (CD37, CD53, TAPA-1, and R2/C33) with MHC Class II Glycoproteins,” Immunogenetics 39(4):249-256, Springer-Verlag, Germany (1994). [cited by applicant]
Awan, F., et al., “Phase 1 Study of TRU-016, an Anti-CD37 SMIP Protein in Naive and Relapsed and/or Refractory CLL Patients,” ASH Annual Meeting 642: Abstract #1792 poster, p. 1, United States (Nov. 2011). Accessed at: … [cited by applicant]
Awan, F.T., et al., “Phase 1 Study of TRU-016, an Anti-CD37 SMIP™ Protein in Naive and Relapsed and/or Refractory CLL Patients,” Blood (ASH Annual Meeting Abstracts) 118(21): Abstract 1792, pp. 1-2, United States (Nov. … [cited by applicant]
Barrena, S., et al., “Aberrant Expression of Tetraspanin Molecules in B-cell Chronic Lymphoproliferative Disorders and its Correlation with Normal B-cell Maturation,” Leukemia 19(8):1376-1383, Nature Publishing Group, U… [cited by applicant]
Beckwith, K.A., et al.,“The CD37-Targeted Antibody-Drug Conjugate IMGN529 is Highly Active against Human CLL and in a Novel CD37 Transgenic Murine Leukemia Model,” Leukemia 28(7):1501-1510, Nature Publishing Group, Unit… [cited by applicant]
Bernstein, I.D., et al., “High Dose Radiolabeled Antibody Therapy of Lymphoma,” Cancer Research 50(3 Suppl):1017s-1021s, American Association for Cancer Research, United States (1990). [cited by applicant]
Blanc, V., et al., “SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies,” Clinical Cancer Research 17(20):6448-6458, American Association for Cancer Research, United States (2011). [cited by applicant]
Braslawsky, G.R., et al., “Antitumor Activity of Adriamycin (hydrazone-linked) Immunoconjugates Compared with Free Adriamycin and Specificity of Tumor Cell Killing,” Cancer Research 50(20):6608-6614, American Associatio… [cited by applicant]
Business Wire, “ImmunoGen, Inc. Announces Presentations at the 102nd Annual Meeting of the American Associated for Cancer Research,” May 30, 2011, accessed at URL:[http://files.shareholder.cornjdownloads/ABEA-5VU3S1/0x0… [cited by applicant]
Cragg, M.S., et al., “Complement-mediated Lysis by Anti-CD20 mAb Correlates with Segregation into Lipid Rafts,” Blood 101(3):1045-1052, American Society of Hematology, United States (Feb. 2003). [cited by applicant]
Dahle, J., et al., “Evaluating Antigen Targeting and Anti-tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin's Lymphoma,” Anticancer Research 33(1):85-96, International Institute of Anticancer Re… [cited by applicant]
Daniel, C., et al., “Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: A Combination of Nine Prediction Algorithms Fails To Identify Relevant Episodes a… [cited by applicant]
De Pascalis, R., et al., “Grafting of ‘Abbreviated’ Complementarity-determining Regions Containing Specificity-determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibo… [cited by applicant]
Deckert, J., et al., “A Novel Anti-CD37 Antibody-Drug Conjugate with Multiple Anti-tumor Mechanisms for the Treatment of B-Cell Malignancies,” Blood 122(20):3500-3510 American Society of Hematology, United States (2013). [cited by applicant]
Deckert, J., et al., “IMGN529: A Therapeutic Maytansinoid Conjugate of an Anti-CD37 Antibody with Multiple Mechanisms of Action for B-cell Lymphoma and Leukemia,” AACR Poster Abstract #2, United States, Apr. 2-6, 2011. [cited by applicant]
Deckert, J., et al., “IMGN529: An Anti-CD37 Antibody-Maytansinoid Conjugate with Multiple Mechanisms of Actions for B-Cell Malignancies,” Keystone Symphosis—B Cells: New Insights into Normal versus Dysregulated Function… [cited by applicant]
Deckert, J., et al., “Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies,” ASH 2011, Abstract #3726, United States (Nov. 2011). [cited by applicant]
Dijoseph, J.F., et al., “CD20-specific Antibody-targeted Chemotherapy of Non-Hodgkin's B-cell Lymphoma Using Calicheamicin-conjugated Rituximab,” Cancer Immunol Immunother 56(7):1107-1117, Springer-Verlag, Germany (2007… [cited by applicant]
Ducry, L., et al., “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate 21:5-13, American Chemical Society, United States (2009). [cited by applicant]
Extended European Search Report and Written Opinion for EP Application No. 13 77 0074, The Hague, Netherlands, completed on Oct. 20, 2015, pp. 1-9. [cited by applicant]
Greenfield, R.S., et al., “Evaluation in Vitro of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker,” Cancer Research 50(20):6600-6607, American Association for Cancer Research, United Sta… [cited by applicant]
Greenspan, N.S. and Di Cera, E., “Defining Epitopes: It's not as Easy as it Seems,” Nature Biotechnology 17(10):936-937, Nature Publishing Group, United States (1999). [cited by applicant]
Gussow, D. and Seemann, G., “Humanization of Monoclonal Antibodies,” Methods in Enzymology 203:99-121, Elsevier Science, United States (1991). [cited by applicant]
Harris, C.L., et al., “Tumour Cell Killing Using Chemically Engineered Antibody Constructs Specific for Tumour Cells and the Complement Inhibitor CD59,” Clinical & Experimental Immunology 107(2):364-371, Blackwell Publi… [cited by applicant]
Heider, K.H., et al., “A Novel Fc-engineered Monoclonal Antibody to CD37 with Enhanced ADCC and High Proapoptotic Activity for Treatment of B-cell Malignancies,” Blood 118(15):4159-4168, The American Society of Hematolo… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/031648, The International Bureau of WIPO, Switzerland, mailed Oct. 2, 2013, pp. 1-9. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US11/28172, International Searching Authority, United States, mailed Jul. 13, 2011, pp. 1-9. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US12/31648, Commissioner for Patents, United States, mailed Sep. 20, 2012, 17 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US15/30371, Commissioner for Patents, United States, mailed on Nov. 2, 2015, pp. 1-10. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/034646, Commissioner for Patents, United States, mailed on Sep. 16, 2013. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/035558, Commissioner for Patents, United States, mailed on Sep. 7, 2016, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/048887, Commissioner for Patents, United States, mailed on Nov. 29, 2016, 8 pages. [cited by applicant]
Kaminski, M.S., et al., “Imaging, Dosimetry, and Radioimmunotherapy with Iodine 131-labeled Anti-CD37 Antibody in B-cell Lymphoma,” Journal of Clinical Oncology 10(11):1696-1711, American Society of Clinical Oncology, U… [cited by applicant]
Knobeloch, K.P., et al., “Targeted Inactivation of the Tetraspanin CD37 Impairs T-cell-dependent B-cell Response Under Suboptimal Costimulatory Conditions,” Molecular and Cellular Biology 20(15):5363-5369, American Soci… [cited by applicant]
Kovtun, Y., et al., “Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance,” Cancer Research 70(6):2528-2537, American Association for Cancer Research, United States (Mar. 2010). [cited by applicant]
Lai, K.C., et al., “The CD37-targeting ADC IMGN529 Combines the Potent Anti-cancer Activity of K7153A Antibody with Efficient Maytansinoid Delivery,” AACR-EORTC-NCI 2011, Poster Abstract #B209, p. 1, United States (Nov.… [cited by applicant]
Lai, K.C., et al., “The CD37-targeting ADC IMGN529 Combines the Potent Anti-cancer Activity of K7153A Antibody with Efficient Maytansinoid Delivery,” Oasis, The Online Abstract Submission System, Abstract 11-A-226-AACR:… [cited by applicant]
Lambert, J.M., “Antibody-Maytansinoid Conjugates: A New Strategy for the Treatment of Cancer,” Drugs of the Future 35(6):471-480, Prous Science, S.A.U., Spain (Jun. 2010). [cited by applicant]
Lapalombella, R., et al., “Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals,” Cancer Cell 21(5):694-708, Elsevier Inc., United States (2012). [cited by applicant]
Link, M.P., et al., “A Unique Antigen on Mature B Cells Defined by a Monoclonal Antibody,” The Journal of Immunology 137(9):3013-3018, The American Association of Immunologists, United States (1986). [cited by applicant]
Lippincott-Schwartz, J., “Antibodies as Cell Biological Tools,” Current Protocols in Cell Biology, 16.0.1-16.0.2, John Wiley & Sons, United States (2002). [cited by applicant]
MacCallum, R.M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology 262(5):732-745, Academic Press, United Kingdom (Oct. 1996). [cited by applicant]
Maecker, H.T., et al., “The Tetraspanin Superfamily: Molecular Facilitators,” FASEB Journal 11(6):428-442, The Federation, United States (1997). [cited by applicant]
Mariuzza, R.A., et al., “The Structural Basis of Antigen-antibody Recognition,” Annual Review of Biophysics and Biomolecular Structure 16:139-159, Annual Reviews, United States (1987). [cited by applicant]
Marken, J.S., et al., “Membrane Topology of the L6 Antigen and Identification of the Protein Epitope Recognized by the L6 Monoclonal Antibody,” The Journal of Biological Chemistry 269(10):7397-7401, American Society for… [cited by applicant]
Meyer-Wentrup, F., et al., “Dectin-1 Interaction with Tetraspanin CD37 Inhibits IL-6 Production,” The Journal of Immunology 178(1):154-162, The American Association of Immunologists, Inc., United States (2007). [cited by applicant]
Moore, K., et al., “Use of the Monoclonal Antibody WR17, Identifying the CD37 gp40-45 Kd Antigen Complex, in the Diagnosis of B-lymphoid Malignancy,” Journal of Pathology 152(1):13-21, John Wiley & Sons, Ltd., United Ki… [cited by applicant]
Morris, G.E., “Epitope Mapping of Protein Antigens by Competition ELISA,” The Protein Protocols Handbook 1:595-600, Humana Press, United States (1996). [cited by applicant]
Office Action dated Oct. 8, 2015 in Russian Patent Application No. 2012139045, filed Mar. 11, 2011, Applicant: Immunogen, Inc, US, pp. 1-12. [cited by applicant]
Pagel, J.M, et al., “Phase 1 Study of TRU-016, An Anti-CD37 SMIPTM Protein in Relapsed and/or Refractory NHL Patients,” Blood (ASH Annual Meeting Abstracts) 118(21): Abstract 1636, The American Society of Hematology, Un… [cited by applicant]
Park, P.U., et al., “Antibody and Linker Selection for the Anti-CD37 Antibody-maytansinoid Conjugate IMGN529 for the Treatment of B-cell Malignancies,” Experimental and Molecular Therapeutics Session, AACR Annual Meetin… [cited by applicant]
Paul, W.E., “Immunogenicity and Antigen Structure,” in [cited by applicant]
Pinkas, J., “Antibody Maytansinoid Conjugates for the Treatment of Cancer,” Protein Therapeutics Forum 2012:1-23, United States (Jan. 30, 2012). [cited by applicant]
Polson, A.G., et al., “Antibody-drug Conjugates For the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-drug Selection,” Cancer Research 69(6):2358-2364, American Association for Cancer Research, United States (2… [cited by applicant]
Preissuance Submission by Third Party under 37 C.F.R. § 1.290 in U.S. Appl. No. 13/045,693 (inventors Deckert et al., filed Mar. 11, 2011) dated May 30, 2013, 14 pages. [cited by applicant]
Preissuance Submission by Third Party under 37 C.F.R. § 1.290 in U.S. Appl. No. 13/436,528 (inventors Deckert et al., filed Mar. 30, 2012), dated Aug. 26, 2013, 15 pages. [cited by applicant]
Preissuance Submission by Third Party under 37 C.F.R. § 1.290 in U.S. Appl. No. 13/796,768 (inventors Deckert et al., filed Mar. 12, 2013), dated Apr. 1, 2014, 18 pages. [cited by applicant]
Press, O.W., et al., “Endocytosis and Degradation of Monoclonal Antibodies Targeting Human B-cell Malignancies,” Cancer Research 49(17):4906-4912, American Association for Cancer Research, United States (1989). [cited by applicant]
Press, O.W., et al., “Radiolabeled-antibody Therapy of B-cell Lymphoma with Autologous Bone Marrow Support,” The New England Journal of Medicine 329(17):1219-1224, Massachusetts Medical Society, United States (1993). [cited by applicant]
Press, O.W., et al., “Retention of B-cell-specific Monoclonal Antibodies by Human Lymphoma Cells,” Blood 83(5):1390-1397, The American Society of Hematology, United States (1994). [cited by applicant]
Press, O.W., et al., “Treatment of Refractory Non-Hodgkin's Lymphoma with Radiolabeled MB-1 (anti-CD37) Antibody,” Journal of Clinical Oncology 7(8):1027-1038, American Society of Clinical Oncology, United States (1989). [cited by applicant]
Robak, T., et al., “TRU-016, a Humanized Anti-CD37 IgG Fusion Protein for the Potential Treatment of B-cell Malignancies,” Current Opinion in Investigational Drugs 10(12):1383-1390, Thomson Reuters Ltd., United Kingdom … [cited by applicant]
Roguska, M.A., et al., “A Comparison of Two Murine Monoclonal Antibodies Humanized by CDR-grafting and Variable Domain Resurfacing,” Protein Engineering 9(10):895-904, Oxford University Press, United Kingdom (1996). [cited by applicant]
Roguska, M.A., et al., “Humanization of Murine Monoclonal Antibodies through Variable Domain Resurfacing,” Proceedings of the National Academy of Sciences USA 91(3):969-973, National Academy of Sciences, United States (… [cited by applicant]
Rops, A.L., et al., “The Tetraspanin CD37 Protects Against Glomerular IgA Deposition and Renal Pathology,” American Journal of Pathology 176(5):2188-2197, American Society for Investigative Pathology, United States (May… [cited by applicant]
Rudikoff, S., et al., “Single Amino Acid Substitution Altering Antigen-binding Specificity,” Proceedings of the National Academy of Sciences of the United States of America 79(6):1979-1983, National Academy of Sciences,… [cited by applicant]
Schwartz-Albiez, R., et al., “The B Cell-associated CD37 Antigen (gp40-52). Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein,” The Journal of Immunology 140(3):905-914, The American Assoc… [cited by applicant]
Sheng, K-C., et al., “Tetraspanins CD37 and CD151 Differentially Regulate Ag Presentation and T-cell co-stimulation by DC,” European Journal of Immunology 39(1):50-55, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2009). [cited by applicant]
Supplementary European Search Report for Application No. EP11754195, mailed on Sep. 10, 2013, 7 pages. [cited by applicant]
Tedder, T.F., et al., “Structure of the Gene Encoding the Human B Lymphocyte Differentiation Antigen CD20 (B1),” The Journal of Immunology 142(7):2560-2568, The American Association of Immunologists, United States (1989… [cited by applicant]
Teicher, B.A. and Chari, R.V.J., “Antibody Conjugate Therapeutics: Challenges and Potential,” Clinical Cancer Research 17(20):6389-6397, American Association for Cancer Research, United States (Oct. 2011). [cited by applicant]
Van Spriel, A.B., et al., “A Regulatory Role for CD37 in T Cell Proliferation,” The Journal of Immunology 172 (5):2953-2961, The American Association of Immunologists, United States (2004). [cited by applicant]
Van Spriel, A.B., et al., “The Tetraspanin Protein CD37 Regulates IgA Responses and Anti-Fungal Immunity,” PLoS Pathogens 5(3) e1000338:1-11, Public Library of Science, United States (2009). [cited by applicant]
Written Opinion for Singapore Patent Application No. 10201501803Y, dated Sep. 4, 2018, Intellectual Property Office of Singapore, Singapore, 6 pages. [cited by applicant]
Yu, B., et al., “Targeted Drug Delivery and Cross-Linking Induced Apoptosis with Anti-CD37 based Dual-Ligand Immunoliposomes in B Chronic Lymphocytic Leukemia Cells,” Biomaterials 34(26):6185-6193, Elsevier Science, Net… [cited by applicant]
Zhao, X., et al., “CD37 is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma,” Blood 116(21), 1 page, American Society of Hematology, United States (Nov. 2011); 52nd Annual Meeting of the American Society o… [cited by applicant]
Zhao, X., “Targeting CD37 and folate receptor for cancer therapy: strategies based on engineered proteins and liposomes,” Europe PubMed Central, accessed at URL:[http://europepmc.org/theses/ETH/6183], accessed on Dec. 9… [cited by applicant]
Zhao, X.B., et al., “Novel Anti-CD37 Small Modular Immunopharmaceutical (SMP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLIJ Cells,” Blood 104, Abstract 2515, 1 page, ASII Annual Meeting, American … [cited by applicant]
Zhao, X.B. et al., “Targeting CD37-positive Lymphoid Malignancies with a Novel Engineered Small Modular Immunopharmaceutical,” Blood 110(7):2569-2577, The American Society of Hematology, United States (2007). [cited by applicant]
Office Action mailed May 16, 2018, in U.S. Appl. No. 15/130,667, inventor Deckert; Jutta, et al., filed Apr. 15, 2016, 6 pages. [cited by applicant]
Office Action mailed Oct. 31, 2017, in U.S. Appl. No. 15/130,667, inventor Deckert; Jutta, et al., filed Apr. 15, 2016, 19 pages. [cited by applicant]
Office Action mailed Apr. 28, 2017, in U.S. Appl. No. 15/130,667, inventor Deckert; Jutta, et al., filed Apr. 15, 2016, 15 pages. [cited by applicant]
Smith, S.M., et al., “The Impact of MYC Expression in Lymphoma Biology: Beyond Burkitt Lymphoma,” Blood Cells, Molecules and Diseases 45(4):317-323, Academic Press, United States (Dec. 2010). [cited by applicant]
Ackler, S., et al., “The Bcl-2 Inhibitor ABT-263 Enhances the Response of Multiple Chemotherapeutic Regimens in Hematologic Tumors in Vivo,” Cancer Chemotherapy and Pharmacology 66(5):869-880, Springer Verlag, Germany (… [cited by applicant]
Algate, P., et al., “TRU-016, An Anti-CD37 SMIP (TM) Biologic, In combination with Other therapeutic Drugs in Models of Non-Hodgkin's Lymphoma,” Blood 116(21):3931, American Society of Hematology, United States (2010), … [cited by applicant]
Alley, S.C., et al., “Antibody-drug Conjugates: Targeted Drug Delivery for Cancer,” Current Opinion in Chemical Biology 14(4):529-537, Elsevier, United Kingdom (2010). [cited by applicant]
Awan, F., et al., “Phase 1 Study of TRU-016, an Anti-CD37 SMIP Protein in Naïve and Relapsed and/or Refractory CLL Patients,” Poster 1792, 1 page, 2011 American Society of Hematology Annual Meeting (Dec. 10, 2011), San … [cited by applicant]
Beers, S.A., et al., “Type II (Tositumomab) Anti-CD20 Monoclonal Antibody Out Performs Type I (Rituximab-Like) Reagents in B-Cell Depletion Regardless of Complement Activation,” Blood 112(10):4170-4177, American Society… [cited by applicant]
Bissery, M., et al., “Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue,” Cancer Research 51(18):4845-4852, American Association for Cancer Research, United States (1991). [cited by applicant]
Boross, P. and Leusen, J.H., “Mechanisms of Action of CD20 Antibodies,” American Journal of Cancer Research 2(6):676-690, e-Century Publishing Corporation, United States (2012). [cited by applicant]
Chen, R., et al., “A Phase II Study of Vorinostat and Rituximab for Treatment of Newly Diagnosed and Relapsed/refractory Indolent Non-hodgkin Lymphoma,” Haematologica 100(3):357-362, Ferrata Storti Foundation, Italy (Ma… [cited by applicant]
Cheson, B.D., et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology 25(5):579-586, American Society of Clinical Oncology, United States (2007). [cited by applicant]
Deckert, et al, “Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion by IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC), ” Poster #3119, 2 pages, 57th ASH Annual Meeting and Expo… [cited by applicant]
Deckert, J., et al., “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” Blood 126(23):1548, 4 pages American Society of Hemato… [cited by applicant]
Deckert, J., et al., “Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion by IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC),” 56th ASH Annual Meeting and Exposition: Abstract #3… [cited by applicant]
Tomayko. M.M. and Reynolds, C.P., “Determination of Subcutaneous Tumor Size in Athymic (Nude) Mice,” Cancer Chemotherapy and Pharmacology 24(3):148-154, Springer Verlag, Germany (1989). [cited by applicant]
Epstein, A.L., et al., “Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors,” The Journal of … [cited by applicant]
Gaudio, E., et al., “Identification Of Anti-Lymphoma Biomarkers Of Response To The Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529,” presented at 58th Annual Meeting and Exposition of the American Society of Hematology … [cited by applicant]
Friedberg, J.W., “Double-Hit Diffuse Large B-cell Lymphoma,” Journal of Clinical Oncology 30(28):3439-3443, American Society of Clinical Oncology, United States (2012). [cited by applicant]
Goel, M., et al., “Plasticity Within the Antigen-combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” Journal of Immunology 173(12):7358-7367, American Association of Immunologists, United S… [cited by applicant]
Gopal, A., et al., “Phase 1b Study of otlertuzumab (TRU-016), an Anti-CD37 monospecific ADAPTIR™ therapeutic protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma patients,” Investigation… [cited by applicant]
Green, T.M., et al., “Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Pred… [cited by applicant]
Gross, J., “3333: Evaluation of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR™M Therapeutic in Preclinical Combination Studies with Kinase Inhibitors and a Next Generation Anti-CD20 Mab in Vitro and in Animal Models of N… [cited by applicant]
Hicks, S.W., et al., “The Antitumor Activity of IMGN529, a CD37-targeting Antibody-drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models,” Neoplasia 19(9):661-671, Neoplasia Press, United States (Se… [cited by applicant]
Hu, S., et al., “MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: a Report from The I… [cited by applicant]
International Preliminary report on patentability for International Application No. PCT/US2016/035558, International search authority, Switzerland, mailed on Dec. 12, 2017, 8 pages. [cited by applicant]
International Search Report with Written Opinion for International Application No. PCT/IB2017/056841, International Searching Authority, Netherlands, mailed Feb. 2, 2018, 10 pages. [cited by applicant]
Khan, T and Salunke, D.M, “Adjustable Locks and Flexible Keys: Plasticity of Epitope-paratope Interactions in Germline Antibodies,” Journal of Immunology 192(11):5398-5405, American Association of Immunologists, United … [cited by applicant]
Konig, A., et al., “Basic Fibroblast Growth Factor (bFGF) Upregulates the Expression of bcl-2 in B Cell Chronic Lymphocytic Leukemia Cell Lines Resulting in Delaying Apoptosis,” Leukemia 11(2):258-265, Nature Publishing… [cited by applicant]
Lai, K.C., et al., “Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay,” Pharmaceutical Research 32(11):3593-3603, Kluwer Academic, United States (2015). [cited by applicant]
Lai, K.C., et al., “The CD37-targeting ADC IMGN529 Combines the Potent Anti-cancer Activity of K7153A Antibody with Efficient Maytansinoid Delivery,” AACR-EORTC-NCI 2011, Poster, 1 page, United States (Nov. 2011). [cited by applicant]
Lim, S.H., et al., “Anti-CD20 Monoclonal Antibodies: Historical and Future Perspectives,” Haematologica 95(1):135-143, Ferrata Storti Foundation, Italy (Jan. 2010). [cited by applicant]
NCT01534715, “IMGN529 in Treating Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma,” retrieved from URL:[https://clinical.gov/archive/NCT01534715/2012_02_16], retrieved on Sep. 6, 2016, 2 pages. [cited by applicant]
Oki, Y., et al., “Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-chop Chemotherapy for Elderly Patients With Diffuse Large B-cell Lymphoma: an Open Label, Single Arm, Phase II Trial,” C… [cited by applicant]
Pers, J.O., et al., “Anti-CD20 Antibody-Mediated Apoptosis of B Cells Is a Lipid Raft-Dependent Process,” Annals of the Rheumatic Diseases 70(Suppl 2):A73, BMJ Publishing Group Ltd., United Kingdom (Feb. 2011). [cited by applicant]
Poosarla, V.G., et al., “Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity,” Biotechnology and Bioengineering 114(6):1331-1342, Wiley, United States (Jun. 2017). [cited by applicant]
Zhao, X., “Targeting CD37 and folate receptor for cancer therapy: strategies based on engineered proteins and liposomes,” Ohio Link Electronic Theses & Dissertations Center, document number osul 174678307, pp. 1-314, Th… [cited by applicant]
Robak, T. and Robak, E., “New Anti-CD20 Monoclonal Antibodies for the Treatment of B-cell Lymphoid Malignancies,” BioDrugs 25(1):13-25, Springer International, New Zealand (Feb. 2011). [cited by applicant]
Romanelli, A., et al., Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models, presented at 13th International Conference… [cited by applicant]
Rudolph, C., et al., “Molecular Cytogenetic Characterization of the Mantle Cell Lymphoma Cell Line GRANTA-519,” Cancer Genetics and Cytogenetics 153(2):144-150, Elsevier, United States (2004). [cited by applicant]
Smith, T.J., et al., “2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-based Clinical Practice Guideline,” Journal of Clinical Oncology 24(19):3187-3205, American Society of Cli… [cited by applicant]
Smolewski, P., et al., “Pro-apoptotic Effect of an Anti-CD37 scFv-Fc Fusion Protein, in Combination With the Anti-CD20 Antibody, Ofatumumab, on Tumour Cells From B-cell Malignancies,” European Journal of Cancer 50(15):2… [cited by applicant]
Stathis, A et al., “Preliminary Findings from a Phase I, Multi-center, Open-label Study of the anti-CD37 Antibody-Drug Conjugate (ADC), IMGN529, in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL),”… [cited by applicant]
Stathis, A. et al., “A Phase I Study Of IMGN529, An Antibody-Drug Conjugate (ADC) Targeting CD37, In Adult Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL),” 56th ASH Annual Meeting and Exposition: Abstra… [cited by applicant]
Stathis, A et al., “A Phase I Study Of IMGN529, An Antibody-Drug Conjugate (ADC) Targeting CD37, In Adult Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL),” Abstract #1760, ASH Annual Meeting, San Francis… [cited by applicant]
Stathis, A., et al., “Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose escalation phase I st… [cited by applicant]
Tedoldi, S., et al., “Selective Loss of B-Cell Phenotype in Lymphocyte Predominant Hodgkin Lymphoma,” Pathology 213(4):429-440, John Wiley and Sons, United Kingdom (Dec. 2007). [cited by applicant]
Co, M.S., et al., “Chimeric and Humanized Antibodies With Specificity for the CD33 Antigen,” Journal of immunology (Baltimore, MD.:1950), 148(4):1149-1154, American Association of Immunologists, United States (Feb. 1992… [cited by applicant]
Deckert, J., et al., “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” poster #1548. 1 page, 57th ASH Annual Meeting and Expo… [cited by applicant]
Gershoni, J.M., et al., “Epitope Mapping: the First Step in Developing Epitope-based Vaccines,” BioDrugs 21(3):145-156, Springer International, New Zealand (2007). [cited by applicant]
Tutt, A., et al., “Trispecific F(ab′)3 Derivatives that use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” The Journal of Immunology 147:60-69, The American As… [cited by applicant]
Wang, L., et al., “Structural Characterization of the Maytansinoid-Monoclonal Antibody Immunoconjugate, huN901-DM1, by mass spectrometry,” Protein Science, 14(9):2436-2446, Cold Spring Harbor Laboratory Press, United St… [cited by applicant]
Wang, Z., et al., “Universal PCR Amplification of Mouse Immunoglobulin Gene Variable Regions: the Design of Degenerate Primers and an Assessment of the Effect of DNA Polymerase 3′ to 5′ Exonuclease Activity,” Journal of… [cited by applicant]
Zenz, T., et al., “Exceptional In Vitro Activity of CD37 Antibodies in CLL,” Blood 116(21):1021-1022, 2010 ASH Annual Meeting Abstracts (Abstract 2460), 5 pages, American Society of Hematology, United States (Nov. 2010)… [cited by applicant]
Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Research in Immunology 145(1):33-36, Elsevier, France (Jan. 1994). [cited by applicant]
Office Action mailed Jan. 21, 2016 in U.S. Appl. No. 13/436,528, inventors Deckert, J., et al., filing date Mar. 30, 2012, 8 pages. [cited by applicant]
Office Action mailed Mar. 30, 2015 in U.S. Appl. No. 13/436,528, inventors Deckert, J., et al., filing date Mar. 30, 2012, 10 pages. [cited by applicant]
Office Action mailed Mar. 7, 2014 in U.S. Appl. No. 13/436,528, inventors Deckert, J., et al., filing date Mar. 30, 2012, 14 pages. [cited by applicant]
Office Action mailed Sep. 8, 2015 in U.S. Appl. No. 13/436,528, inventors Deckert, J., et al., filing date Mar. 30, 2012, 8 pages. [cited by applicant]
Heppner, G.H., et al., “Tumor heterogeneity: biological implications and therapeutic consequences,” Cancer Metastasis Rev. 2(1):5-23, Martinus Nihoff Publishers, Netherlands (1983). [cited by applicant]
International Search Report and Written Opinion mailed Aug. 21, 2019, in International Application No. PCT/IB2019/054457, European Patent Office, Netherlands, 11 pages. [cited by applicant]
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,” Scientific American 271(1):58-65, Scientific American Inc., United States (Jul. 1994). [cited by applicant]
Zhao, X., et al., “CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma,” Blood: 2010 ASH Annual Meeting Abstracts 116(21):1277-1278, Abstract #3098, 2 pages, American Society of Hematology, United Sta… [cited by applicant]
Deckert, J., et al., “IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models,” poster #1548, 1 page, 57th ASH Annual Meeting and Expo… [cited by applicant]
Deckert, J., et al., “Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion by IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC),” 56th ASH Annual Meeting and Exposition: Poster, 1 p… [cited by applicant]
Epstein, A.L., et al., “Two New Monoclonal Antibodies, Lym-1 and Lym-2, Reactive With Human B-lymphocytes and Derived Tumors, With Immunodiagnostic and Immunotherapeutic Potential,” Cancer Research 47(3):830-840, Americ… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/048887, International Searching Authority, United States, issued Mar. 6, 2018, 5 pages. [cited by applicant]
Levy, M. Y., et al., “Safety and efficacy of CD37-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and Other Non-Hodgkin's B-cell Lymphomas—a Phase 2 Study,” Poster #244, presented at the … [cited by applicant]
Malia, T. J., et al., “Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8,” Proteins 84(4):427-434, John Wiley & Sons, United States (Apr. 2016). [cited by applicant]
De Genst, E., et al., “Antibody repertoire development in camelids,” Developmental and Comparative Immunology 30(1-2):187-198, Elsevier, Netherlands (2006). [cited by applicant]
Ward, E. S., et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Barthelemy, P. A., et al., “Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains,” Journal of Biological Chemistry 283(6):3639-3654, Elsevier, Netherlands (Fe… [cited by applicant]
Choi, Y., and Deane, C. M., “Predicting antibody complementarity determining region structures without classification,” Molecular BioSystems 7(12):3327-3334, Royal Society of Chemistry, United Kingdom (Dec. 2011). [cited by applicant]
Griffiths, A. D., et al., “Human anti-self antibodies with high specificity from phage display libraries,” EMBO J 12(2):725-734, European Molecular Biology Organization, Germany (Feb. 1993). [cited by applicant]
Klimka, A., et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” British Journal of Cancer 83(2):252-260, Nature Publishing Group, United Kingdom (Jul. 2000). [cited by applicant]
Beiboer, S. H., et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent,” Journal of… [cited by applicant]